Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pressure Builds On Neulasta As EMA Accepts Biosimilar Filings

This article was originally published in Scrip

Executive Summary

Amgen's Neulasta (pegfilgrastim) is coming under increasing competitive pressure after the European Medicines Agency revealed that its scientific committee, the CHMP, has two biosimilar versions of the neutropenia drug under review.